Moscona, A. Neuraminidase inhibitors for influenza. N. Engl. J. Med.
353 (2005) 1363–1367.
Matrosovich, M.N., Matrosovitch, T.Y., Gray, T, Roberts, N.A. and Klenk, H.D. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J. Virol.
78 (2004) 12665–12667.
Gubareva, L.V., Kaiser, L. and Hayden, F.G. Influenza virus neuraminidase inhibitors. Lancet
355 (2000) 827–835.
Englund, J.A. Antiviral therapy of influenza. Sem. in Ped. Infect. Dis.
13 (2002) 120–128.
Stiver, G. The treatment of influenza with antiviral drugs. CMAJ
168 (2003) 49–57.
Colman, P.M. A novel approach to antiviral therapy for influenza. J. Antimicrob. Chemother.
44 (1999) 17–22.
Brandtzaeg, P., Farstad, I.N., Johansen, F.E., Morton, H.C., Norderhaug, I.N. and Yamanaka, T. The B-cell system of human mucosae and exocrine glands. Immunol. Rev.
171 (1999) 45–87.
Tomana, M., Kulhavy, R. and Mestecky, J. Receptor-mediated binding and uptake of IgA by human liver. Gastroenterology
94 (1988) 762–770.
Groh, V., Porcelli, S., Fabbi, M., Lanier, L.L., Picker, L.J., Anderson, T., Warnke, R.A., Bhan, A.K., Strominger, J.L. and Brenner, M.B. Human lymphocyes bearing T cell receptor gamma/delta are phenotypically diverse and evenly distributed throughout the lymphoid system. J. Exp. Med.
169 (1989) 1277–1294.
Spencer, J., Isaacson, P.G., Diss, T.C. and MacDonald, T.T. Expression of disulfide-linked and non-disulfide-linked forms of the T cell receptor gamma/delta heterodimer in human intestinal intraepithelial lymphocytes. Eur. J. Immunol.
19 (1989) 1335–1338.
Deusch, K., Luling, F., Reich, K., Classen, M., Wagner, H. and Pfeffer, K.A major fraction of human intraepithelial lymphocytes simultaneously expresses the gamma/delta T cell receptor, the CD8 accessory molecule and preferentially uses the V delta1 gene segment. Eur. J. Immunol.
21 (1991) 1053–1059.
Jones, W.M., Walcheck, B. and Jutila, M.A. Generation of a new gamma/delta T cell-specific monoclonal antibody (GD3.5). J. Immunol.
156 (1996) 3772–3779.
Floyd, H., Nitschke, L. and Crocker, P.R. A novel subset of murine B cells that expresses unmasked forms of CD22 is enriched in the bone marrow: Implications for B-cell homing to the bone marrow. Immunology
101 (2000) 342–347.
Nitschke, L., Floyd, H. and Ferguson, D.J., Identification of CD22 ligands on CD22 bone marrow sinusoidal endothelium implicated in CD22-dependent homing of recirculating B-cells. J. Exp. Med.
189 (1999) 1513–1518.
Reinholdt, J., Tomana, M. and Mortensen, S.B. Molecular aspects of IgA degredation by oral streptococci. Infect. Immunol.
58 (1990) 1186–1194.
Kast R.E. A theory of lymphocyte blast transformation and malignant change based on proteolytic cleavage of the trigger peptide: The detendomer. Oncology
29 (1974) 249–264.
Kast, R.E. Lymphocytes and cells in malignant transformation. Oncology
32 (1975) 175–189.
Gronbaek Frandsen, E.V. Bacterial degradation of IgA1 in relation to periodontal disease. APMIS (Suppl) 87 (1999) 1–54.
King, S.J., Hippe, K.R., Gould, J.M., Bae, D., Peterson, S., Cline, R.T., Fasching, C., Janoff, E.N. and Weiser, J.N. Phase variable desialylation of host proteins that bind to Streptococcus pneumoniae in vivo and protect the airway. Mol. Microbiol.
54 (2004) 159–171.
Kannagi, R. Regulatory roles of carbohydrate ligands for selectins in the homing of lymphocytes. Curr. Opin. Struct. Biol.
12 (2002) 599–608.
Glezen, W.P., Payne, A.A. and Snyder, D.N. Mortality and influenza. J. Infect. Dis.
146 (1982) 313–321.
Simonsen, L, Fukada, K. and Schonberger, L.B. The impact of influenza epidemics on hospitalizations. J. Infect. Dis.
181 (2000) 831–837.
Simonsen, L. The global impact of influenza on morbidity and mortality. Vaccine
17 (Suppl 1) (1999) S3–10.
McCullers, J.A. and Bartmess, K.C. Role of neauraminidase in lethal synergism between influenza virus and streptococcus pneumoniae. J. Infect. Dis.
187 (2003) 1000–1009.
McCullers, J.A. Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza. J. Infect. Dis.
190 (2004) 519–526.
Kaiser, L., Wat, C., Mills, T., Mahoney, P., Ward, P. and Hayden, F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch. Intern. Med.
163 (2003) 1667–1672.
Kaiser, L., Keene, O.N. and Hammond, J.M. Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. Arch Intern Med
160 (2000) 3234–3240.
Treanor, J.J., Hayden, F.G., Vrooman, P.S., Barbarash, R., Bettis, R., Riff, D., Singh, S., Kinnersley, N., Ward, P. and Mills, R.G. Efficacy and safety of oral neuraminidase Inhibitor oseltamivir in treating acute influenza: A randomized controlled trial. JAMA
283 (2000) 1016–1024.
Monto, A.S., Webster, A. and Keene, O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: Pooled efficacy analysis. J. Antimicrob. Chemother.
44 (1999) 23–29.
Peltola, V.T., Murti, K.G. and McCullers, J.A. Influenza virus neuraminidase contributes to secondary bacterial pneumonia. J Infect Dis.
192 (2005) 249–257.
Peltola, V.T. and McCullers, J.A. Respiratory viruses predisposing to bacterial infections: role of neuraminidase. Pediatr. Infect. Dis. J.
23 (Suppl.1) (2004) S87–97.
Yen, H.L., Herlocher, L.M., Hoffmann, E., Matrosovich, M.N., Monto, A.S., Webster, R.G. and Govorkova, E.A. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob. Agents Chemother.
49 (2005) 4075–4084.
Roberts, N. Treatment of influenza with neuraminidase inhibitors: Virological implications. Phil. Trans. R. Soc. Lond.
356 (2001) 1895–1897.
Wakai, K., Nakai, S., Matsuo, S., Kawamura, T., Hotta, N., Maeda, K. and Ohno, Y. Risk factors for IgA nephropathy: A case-control study with incident cases in Japan. Nephron
90 (2002) 16–23.
Xu, L.X. and Zhao, M.H. Aberrantly glycosylated serum IgA1 are closely associated with pathologic phenotypes of IgA nephropathy. Kidney Int.
68 (2005) 167–172.
Altschuler, E.L., Bhatia, A. and Kast, R.E. Consideration of use of neuraminidase inhibitors such as oseltamivir and zanamivir in IgA nephropathy. Kidney Int.
68 (2005) 2910–2911.